Dimethyltryptamine (copyright) occupies a complex and sometimes contradictory legal status across European nations. While some countries have outright banned the substance, others maintain a more ambiguous stance, leaving its legality open to debate. This regulatory ambiguity stems from a variety of factors, including differing societal attitudes t